Sara Siegfried
Nurse Practitioner · Daytona Beach, FLNPI 1467941120
Payments from drug & device makers
Across 64 payments — averaging $41.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$151
- Seagen Inc.$143
- Johnson & Johnson$122
- Bayer$120
- Merck$86
- plus $525 from 17 others
What the payments were for
- Food & beverage$1,25848%
- Education$1998%
- Other$1,18245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $1,492 |
| E.r. Squibb & Sons, L.L.C. | 2 | $151 |
| Seagen Inc. | 3 | $143 |
| Johnson & Johnson | 3 | $122 |
| Bayer | 1 | $120 |
| Merck | 2 | $86 |
| Bristol Myers Squibb | 3 | $79 |
| Stemline Therapeutics Inc. | 3 | $48 |
| AstraZeneca | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Incyte Corporation | 2 | $33 |
| Coherus Oncology, Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $33 |
| AbbVie | 1 | $29 |
| Gilead | 1 | $27 |
| Geron Corporation | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Global Blood Therapeutics, Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,639 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $7,894 |
| Ondansetron Hcl | 18 | $367 |
| Lorazepam | 21 | $256 |
| Dexamethasone | 14 | $221 |
| Prochlorperazine Maleate | 18 | $214 |
| Nystatin | 14 | $204 |
| Levothyroxine Sodium | 14 | $115 |
| Potassium Chloride | 13 | $114 |
| Ondansetron OdtOndansetron | 12 | $98 |
| Gabapentin | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Daytona Beach
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.